Peptide
Reference library
Educational peptide reference — research use only.
Research & educational use only
For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.
The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.
PT-141
A melanocortin receptor agonist studied in central nervous system research.
- Half-life (approx.)
- ~2.7 h (approx.)
- Diluent
- Bacteriostatic water (0.9% benzyl alcohol)
- Common vials
- 10 mg
Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.
Overview
PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist studied for hypoactive sexual desire via central nervous system pathways. Unlike PDE5 inhibitors, its mechanism is neuromodulatory rather than vascular. Bremelanotide — central MC4R agonist approved for hypoactive sexual desire research.
Structure & identity
Cyclic heptapeptide bremelanotide Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]
- Sequence / structure
- Cyclic heptapeptide bremelanotide Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]
Status: FDA-approved (Vyleesi).
Mechanism
FDA-approved (Vyleesi).
MC4R agonist in CNS arousal centers — neuromodulatory rather than vascular mechanism. Neuromodulatory arousal mechanism distinct from peripheral vasodilator drug classes.
Studies & clinical programs
Hypoactive sexual desire trials
Published research models
- Peer-reviewed literature documents endpoints under Hypoactive sexual desire trials experimental designs.
fMRI arousal studies
Published research models
- Peer-reviewed literature documents endpoints under fMRI arousal studies experimental designs.
Research models in literature
- Hypoactive sexual desire trials
- fMRI arousal studies
Literature highlights
- Central MC4R agonist (bremelanotide) studied in hypoactive sexual desire disorder trials.
- fMRI arousal and behavioral endpoints distinguish CNS mechanism from PDE5 vascular approaches.
- FDA-approved (Vyleesi) — neuromodulatory rather than peripheral vasodilator profile.
Key targets & pathways
Research areas
Routes in research literature
Also known as
Stability & storage phases
| Phase | Condition | Guidance |
|---|---|---|
| Lyophilized | Sealed vial, refrigerated (2–8 °C) | Intact lyophilized cake or powder is typically stable for months to years per published stability data; protect from moisture, light, and repeated freeze-thaw of the dry vial. |
| Reconstituted | Bacteriostatic water (0.9% benzyl alcohol), refrigerated | Most aqueous peptide solutions remain usable for approximately 2–4 weeks refrigerated; verify published stability data and label with reconstitution date. |
| Working aliquots | Pre-drawn syringes or microtubes, frozen (−20 °C) | Aliquot promptly after mixing to limit freeze-thaw cycles on the main vial; thaw once and use to reduce protease-mediated degradation. |
Stability windows are formulation-dependent — verify published data and your lab SOP.
Reconstitution reference table
| Vial (mg) | Diluent (mL) | mcg/mL | Units @ 100 mcg | Units @ 250 mcg | Units @ 500 mcg |
|---|---|---|---|---|---|
| 10 | 2 | 5000.0 | 2 | 5 | 10 |
U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.
Reconstitution steps
- Allow vial to reach room temperature (15–30 min)
- Swab rubber stopper with alcohol prep pad
- Draw calculated bacteriostatic water into syringe
- Inject diluent slowly down vial wall — do not spray directly onto cake
- Gently swirl until fully dissolved — do not shake vigorously
- Label with date, concentration, and diluent volume
- Refrigerate and use within your lab stability window
Reconstituted per research protocol; formulation varies by published formulation.
Laboratory record checklist
- Compound identity recorded in lab notebook (name, lot, preparation date)
- Analytical identity cross-checked against published sequence or structure
- Potency or concentration documented from analytical certificate when available
- Purity or HPLC data filed when provided with research material
- Appearance noted: intact lyophilized cake or uniform powder
- Sterility / endotoxin report archived when available
- Storage temperature applied immediately per published stability guidance